刘兆国
师资介绍
刘兆国,男,汉族,1987年11月生,博士,副教授,硕士生导师。
教育经历:
2007.09-2011.06盐城工学院,生物工程,学士
2011.09-2016.06南京中医药大学,中药药理学,博士
工作经历:
2016.07-2016.10 香港浸会大学,博士后
2016.11-2019.06永利集团88304官网集团,永利集团88304官网集团,讲师
2019.07-至今 永利集团88304官网集团,永利集团88304官网集团,副教授
研究方向:
中药药理学(中药复方及其活性成分抗结肠炎/癌及肝纤维化的效应与机制研究)
社会学术兼职:
江苏省药理学会临床前药理专委会委员;江苏省药理学会中药药理委员会委员;江苏省双创人才(科技副总)
基金项目:
国家自然科学基金面上项目,82374228,乌梅丸通过AHCY蛋白介导RIG-I乳酸化修饰调控巨噬细胞极化抗CAC的作用及机制研究,2024/01-2027/12,49万元,在研,主持
国家自然科学基金青年项目,81703884,基于PKCδ介导的自噬调控探究黄葵胶囊对顺铂肾毒性的保护作用及分子机制,2018/01-2020/12,20万元,已结题,主持
中国博士后科学基金面上项目,2018M642296,黄葵胶囊抗顺铂所致肾毒性的机理研究,2018/11-2020/08,5万元,已结题,主持
南通市科技计划项目,JC2021025,基于 MIF/MIOX/铁死亡信号调控探究黄葵胶囊抗顺铂急性肾损伤的机制研究,2021/07-2023/06,5万元,已结题,主持
江苏省高等学校自然科学研究面上项目,17KJB360012,黄葵胶囊对顺铂肾毒性的保护作用及机理研究,2017/09-2019/08,3万元,已结题,主持
科研成果:
近5年侧重于中药复方及其活性成分抗结肠相关疾病(结肠炎、结肠癌)及肝纤维化的效应及机制研究。课题组主要运用细胞模型、整体动物模型结合分子生物学、蛋白质组学、网络药理学及生信分析技术,着力挖掘潜在的抗结肠癌及抗肝纤维化中药复方及中药活性成分,并揭示其发挥作用的机理,为临床研究提供重要实验依据。
研究工作受到国家自然科学基金委员会、中国博士后科学基金会及南通市科技局各类基金项目支持,包括1项国家自然科学基金青年基金项目、1项国家自然科学基金面上项目、1项中国博士后科学基金面上项目、1项南通市科技计划项目支持,取得了一系列具有一定科学价值的研究成果。
在Oxidative Medicine and Cellular Longevity、Journal of Cellular and Molecular Medicine、International Immunopharmacology、International Journal of Molecular Sciences、Biomedicine & Pharmacotherapy及Frontiers in Pharmacology等期刊发表专业学术论文20余篇,其中中科院二区论文15篇,论文累积被引700余次。
成果奖励:
1、南通市首届十佳中药年度人物(2022)
2、永利集团88304官网集团第十二届青年教师讲课竞赛一等奖(2021)
3、永利集团88304官网集团优秀教育工作者(2021)
代表性论文:
1. Weiling Lin#, Bangjie Gu#, Yuayuan Gu#, Rui Zhao, Yumeng Huang, Rui Fan, Weihao Rong*,Zhaoguo Liu*. Taraxasterol protects against acetaminophen-induced hepatotoxicity by reducing liver inflammatory response and ameliorating oxidative stress in mice [J].International Immunopharmacology, 2024, 138: 112580.
2. Zirong Deng#, Yun Xu#, Yuchen Cai, Weiling Lin, Libei Zhang, Aoqing Jiang, Yuhang Zhou, Rui Zhao, Heyan Zhao,Zhaoguo Liu* and Tingdong Yan*. Inhibition of ribosomal RNA Processing 15 homolog (RRP15) suppressed tumor growth, invasion and epithelial to mesen-chymal transition (EMT) of colon cancer [J].International Journal of Molecular Sciences, 2023, 24(4): 3528.
3. Libei Zhang#, Weiling Lin#, Yunqing Cai#, Ziyou Huang, Rui Zhao, Tingdong Yan, HongtaoXu*,Zhaoguo Liu*. Farnesoid X receptor activation is required for the anti-inflammatory and anti-oxidative stress effects of Alisol B 23-acetate in carbon tetrachloride-induced liver fibrosis in mice [J].International Immunopharmacology, 2023, 123:110768.
4. Jue Wang#, Kang Ding#, Yuhang Wang#, Tingdong Yan, Yun Xu, Zirong Deng, Weiling Lin, Libei Zhang, Weizhong Zhu, Rui Zhao, Yuhang Zhou,Zhaoguo Liu*. Wumei Pill ameliorates AOM/DSS-induced colitis-associated colon cancer through inhibition of inflammation and oxidative stress by regulating S-adenosylhomocysteine hydrolase- (AHCY-) mediated hedgehog signaling in mice [J].Oxidative Medicine and Cellular Longevity, 2022, 2022:4061713.
5.Zhaoguo Liu#, Mengjue Tu#, Jiannan Shi#, Hong Zhou, Guoliang Meng, Jianguo Gu*, Yuqin Wang*. Inhibition of fucosylation by 2-fluorofucose attenuated acetaminophen-induced liver injury via its anti-inflammation and anti-oxidative stress effects [J].Frontiers in Pharmacology, 2022, 13:939317.
6. Chang Chen#, Jingya Gu#, Jue Wang#, Yu Wu, Aihua yang, Tingting Chen, Tingting Zhou,Zhaoguo Liu*. Physcion 8-O-β-glucopyranoside ameliorates liver fibrosis through inflammation inhibition by regulating SIRT3-mediated NF-κB P65 nuclear expression [J].International Immunopharmacology, 2021, 90: 107206.
7. Yuqin Wang#, Chunling Li#, Jingya Gu#, Chang Chen, Jiaxin Duanmu, Jing Miao, Wenjuan Yao, Jinhua Tao, Mengjue Tu, Biao Xiong, Lingling Zhao*,Zhaoguo Liu*. Celastrol exerts anti-inflammatory effect in liver fibrosis via activation of AMPK-SIRT3 signaling [J].Journal of Cellular and Molecular Medicine, 2020, 24 (1): 941-953.
8. Jingya Gu#, Chang Chen#, Jue Wang#, Tingting Chen, Wenjuan Yao, Tingdong Yan*,Zhaoguo Liu*. Withaferin A exerts preventive effect on liver fibrosis through oxidative stress inhibition in a sirtuin 3-dependent manner [J].Oxidative Medicine and Cellular Longevity, 2020, 2020: 2452848.
9. Jinlin Zhang, Aihua Yang, Yu Wu, Wei Guan, Biao Xiong, Xiaoqing Peng, Xiaojin Wei, Chang Chen,Zhaoguo Liu*. Stachydrine ameliorates carbon tetrachloride- induced hepatic fibrosis by inhibiting inflammation, oxidative stress and regulating MMPs/TIMPs system in rats [J].Biomedicine & Pharmacotherapy, 2018, 97: 1586-1594.
10.Zhaoguo Liu#,*, Pingting Zhu#, Lin Zhang, Biao Xiong, Jinhua Tao, Wei Guan, Chunling Li, Chang Chen, Jingya Gu, Jiaxin Duanmu, Wei Zhang*. Autophagy inhibition attenuates the induction of anti-inflammatory effect of catalpol in liver fibrosis [J].Biomedicine & Pharmacotherapy, 2018, 103:1262-1271.
11. Lin Zhang#, Chang Chen#, Jiaxin Duanmu, Yan Wu, Jinhua Tao, Aihua Yang, Xiaoqin Yin, Biao Xiong, Jingya Gu, Chunling Li,Zhaoguo Liu*. Cryptotanshinone inhibits the growth and invasion of colon cancer by suppressing inflammation and tumor angiogenesis through modulating MMP/TIMP system, PI3K/Akt/mTOR signaling and HIF-1α nuclear translocation [J].International Immunopharmacology, 2018, 65: 429-437.
12. Pingting Zhu#, Yu Wu#, Aihua Yang, Xingsheng Fu, Ming Mao,Zhaoguo Liu*. Catalpol suppressed proliferation, growth and invasion of CT26 colon cancer by inhibiting inflammation and tumor angiogenesis [J].Biomedicine & Pharmacotherapy, 2017, 95:68-76.